NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company developing treatments for intracranial (brain) malignancies. Its lead candidates, NEO100 (Phase IIa) and NEO212 (Phase I/II), target difficult-to-treat cancers such as glioblastoma and high-grade glioma. With shares trading near $4.85 and a cluster of Wall Street price targets sitting far higher, investors are asking a simple but consequential question: can this micro-cap stock reach $17?
Four verified analyst price targets were reviewed to establish the central target. Roth MKM (analyst Jonathan Aschoff) maintained a Buy with a $20 target in early November 2026, and Maxim Group reiterated a Buy at $20 around the same time. BTIG holds a Buy at $15 (September 2026), and Alliance Global Partners initiated coverage with a Buy at $13 (May 2026). The arithmetic mean of these four targets is $17.00, with a low of $13 and a high of $20.
Because every rating is a Buy, the stock carries a uniformly bullish analyst consensus with no Hold or Sell ratings. The spread between $13 and $20 nevertheless reflects genuine disagreement about how much value the pipeline can unlock. Cautious analysts weigh the company's minimal revenue and financing needs, while more aggressive targets emphasize the large, underserved market for brain-cancer therapies. Note that some third-party aggregators show a slightly different average or target count; the $17 figure here is calculated directly from the four individual, attributable targets above.
The latest verified close is $4.85 (November 12, 2026), with a 52-week range of about $2.50 to $11.81. Reaching $17 would require an upside of roughly 250% from current levels, which is a very large move by any standard. The company generated only about $40,000 in trailing revenue and reported a trailing twelve-month net loss near $47 million, with EPS (earnings per share) around negative $1.95. As a pre-revenue clinical-stage company, it has no meaningful P/E (price-to-earnings) ratio, so valuation rests almost entirely on pipeline potential, clinical data, and financing capacity.
The path toward $17 would almost certainly depend on positive clinical readouts, successful capital raises without excessive dilution, and sustained investor interest in oncology names. The stock has shown sharp swings, gaining more than 50% in the most recent trading week, which underscores both its momentum and its volatility.
The principal support is the pipeline itself. NEO100 and NEO212 target brain cancers with limited treatment options, a high-unmet-need area that can command substantial valuations if data are positive. Recent insider buying, including purchases by the CFO, has signaled internal confidence. A narrower quarterly net loss reported for the September 2026 quarter (about $7.27 million versus roughly $8.62 million a year earlier) also shows modest progress on cost control. Broad sector momentum in biotechnology and renewed risk appetite in small caps could amplify any positive catalyst.
The obstacles are significant. A cash balance near $1.97 million is thin for a company burning tens of millions annually, making additional equity raises likely and raising the risk of dilution, which can pressure the share price. Clinical trials are binary: any delay, safety concern, or failure in NEO100 or NEO212 could sharply reset the valuation. The company has essentially no revenue, ongoing losses, and a negative book value, and as a micro-cap it faces limited liquidity and high sensitivity to broader risk-off sentiment in the market.
From a technical standpoint, $4.85 sits well below the stock's November 2025 high of $11.81 but above the October 2026 low near $2.50, which now acts as the key support level on the downside. The $5.00 mark is a nearby psychological level, while the prior high near $11.81 would represent a significant resistance area on any sustained advance. The $17 target sits far above that prior peak, meaning it would require an entirely new, data-driven re-rating rather than a simple recovery.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may use different assumptions. Investors should monitor clinical trial progress and data readouts for NEO100 and NEO212, quarterly earnings and cash-burn disclosures, any financing or partnership announcements, and changes in analyst targets or ratings. Because the company reports losses, cash runway and dilution are as important to the stock forecast as the clinical pipeline itself.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive ticker like NTHI, such tools can help traders discover opportunities, track positions, and spot changing trends more efficiently than manual review. Traders seeking a systematic edge may find these signals a useful complement to their own research.
The $17 central target, derived from four Buy-rated analyst price targets ranging from $13 to $20, would require a gain of roughly 250% from the current price near $4.85. That is an ambitious move supported mainly by the promise of the company's brain-cancer pipeline, recent insider buying, and uniformly bullish analyst sentiment. Against that stand a thin cash position, ongoing losses, dilution risk, and the binary nature of clinical development. The wide target range reflects genuine uncertainty. Investors should focus on upcoming clinical data, financing news, and analyst revisions rather than treating the average analyst price target as a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that NTHI and NTRB have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTHI and NTRB's prices will move in lockstep.
| Ticker / NAME | Correlation To NTHI | 1D Price Change % | ||
|---|---|---|---|---|
| NTHI | 100% | -16.35% | ||
| NTRB - NTHI | 30% Poorly correlated | +3.73% | ||
| CLYM - NTHI | 26% Poorly correlated | -0.22% | ||
| ABVC - NTHI | 24% Poorly correlated | -3.34% | ||
| DMAC - NTHI | 23% Poorly correlated | -6.64% | ||
| CLRB - NTHI | 23% Poorly correlated | -0.26% | ||
More | ||||